Über

Incidence rises with age, and nearly 70% of men autopsied at age 80–89 had cancer in their prostates. Autopsies of men who died at various ages have shown cancer in the prostates of more than 40% of men over age 50. Less commonly, tumors have aberrant activation of the Wnt signaling pathway via disruption of members APC (9% of tumors) or CTNNB1 (4% of tumors); or dysregulation of the PI3K pathway via PI3KCA/PI3KCB mutations (6% of tumors) or AKT1 (2% of tumors). Similarly, deletions of the tumor suppressor PTEN are harbored by 12–17% of castrate-sensitive tumors, but more than 40% of castrate-resistant tumors. Many of these mutations are in genes that protect from DNA damage, such as p53 (mutated in 8% of localized tumors, more than 27% of metastatic ones) and RB1 (1% of localized tumors, more than 5% of metastatic ones). As the tumor grows, its cells accumulate more mutations, allowing it to stimulate the growth of new blood vessels to support further growth. With these processes dysregulated, some cells replicate abnormally, forming a clump of cells called a tumor.
Prostate-specific antigen (PSA) is a protein produced by the glandular tissue of the prostate (a walnut-sized gland just below the bladder and in front of the rectum in males). This may have clinical implications when screening PSA in men who have occult PCa, though further human clinical trials are needed. It appears that the androgen is a key factor controlling the production of PSA. Although it is known that the production of PSA is androgen-responsive, the exact role of androgens in the PSA production is not well documented. Different concentrations of T were added to different wells on day 4 and PSA level in each well was tested on day 5. Medium was changed to fresh serum free medium (day 0), serum free medium was changed and collected for PSA test every day till day 4.
Data of the included studies were not sufficient to evaluate the risk of prostate cancer with testosterone replacement therapy; however, based on evidence in the literature it does not appear that the risk of prostate cancer is affected by testosterone replacement therapy. Our results show that the serum testosterone level at the time of diagnosis was unrelated to PSA and prostate cancer risk and aggressiveness. In summary, the present study found that the serum testosterone level at the time of diagnosis was unrelated to PSA and prostate cancer risk and aggressiveness. Furthermore, prostate cancer prevalence did not increase as testosterone levels increased.
The demonstration that androgen suppression effectively treats advanced prostate cancer, and the fact that elevated serum androgen levels might predispose people to prostate cancer, have attracted persistent interest. Our main objective was to analyze the relationship between serum testosterone, prostate-specific antigen (PSA), and prostate cancer risk in high-risk patients. A recent study by Morote et al showed that prostate cancer risk and tumor aggressiveness are unrelated to serum testosterone . As of 2024update studies exploring the relationship between ejaculation frequency and prostate cancer risk are inconclusive and age, urinary health, and lifestyle are important factors to consider. After prostatectomy or radiotherapy, those who have a short time between treatment and a subsequent rise in PSA levels, or quickly rising PSA levels are more likely to die from their cancers. Despite reduced testosterone levels, metastatic prostate tumors eventually continue to grow – manifested by rising blood PSA levels, and metastases to nearby bones. For those with metastatic disease, the standard of care is androgen deprivation therapy (also called "chemical castration"), drugs that reduce levels of androgens (male sex hormones) which prostate cells require to grow.
The prostate is an accessory gland of the male reproductive system and a muscle-driven mechanical switch between urination and ejaculation. Several prostate immortalized cell lines are widely used, namely the classic lines DU145, PC-3, and LNCaP, as well as more recent cell lines 22Rv1, LAPC-4, VCaP, and MDA-PCa-2a and −2b. The observation that the testicles (and the hormones they secrete) influence prostate size was made as early as the late 18th century via castration experiments in animals. In the 1970s, Willet Whitmore pioneered an open surgery technique where needles of Iodine-125 were placed directly into the prostate. By the 1960s, this was often combined with hormone therapy to improve the potency of therapy.
The cells lining this part of the urethra differentiate into the glandular epithelium of the prostate. About 20,000 protein-coding genes are expressed in human cells and almost 75% of these genes are expressed in the normal prostate. Disorders of the prostate include enlargement, inflammation, infection, and cancer. Prostate cancer screening and awareness have been widely promoted since the early 2000s by Prostate Cancer Awareness Month in September and Movember in November. In the 1950s the advent of more powerful radiation machines allowed for external beam radiotherapy to reach the prostate. PSA levels greater than 1 ng/mL are generally considered above normal by gender care specialists. As are single-nucleotide polymorphisms in the vitamin D receptor common in African-Americans, and in the androgen receptor, CYP3A4, and CYP17 involved in testosterone synthesis and signaling.
The in vivo experiment results showed that 48% of PCa xenografts carrying mice have serum PSA level lower than 4 ng ml−1. The in vitro data demonstrated that cultured LNCaP cells ceased to produce PSA after androgen withdrawal and resumed PSA production after androgen was re-added. In 2 studies, testosterone was administered transdermally, and in 2 IM. In 4 studies, testosterone was administered transdermally, in 4 IM, and in 1 orally. The primary outcome measure was the change of PSA level between before and after treatment (PSAafter - PSAbefore). Data extracted from studies that met the inclusion criteria were the name of the first author, year of publication, study design, demographic data of individuals, dosage and administration of testosterone, and outcomes. The primary outcome was change of PSA level between before and after treatment.